Bridgewater Associates LP Buys 11,864 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bridgewater Associates LP lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 112,999 shares of the specialty pharmaceutical company’s stock after acquiring an additional 11,864 shares during the period. Bridgewater Associates LP’s holdings in Jazz Pharmaceuticals were worth $12,589,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc boosted its position in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $122.64 on Friday. The firm has a market capitalization of $7.41 billion, a P/E ratio of 17.27, a P/E/G ratio of 1.05 and a beta of 0.57. The company has a fifty day moving average of $114.66 and a 200-day moving average of $111.07. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wells Fargo & Company cut their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.